Newswire (Published: Friday, May 26, 2017, Received: Thursday, May 18, 2017, 3:56:05 PM CDT)

Word Count: 518

New Findings in Prostate Cancer Described from Monash University (Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program)

By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news originating from Melbourne, Australia, by NewsRx correspondents, research stated, "Cabazitaxel is a next generation taxane that has been shown to improve overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed during or after docetaxel-based therapy. A worldwide early access program (EAP) study was established to provide access to cabazitaxel ahead of commercial availability and to evaluate its safety and tolerability."

Financial support for this research came from Sanofi-Aventis Australia Pty Ltd (see also Oncology - Prostate Cancer).

Our news journalists obtained a quote from the research from Monash University, "The Australian EAP included patient-reported outcomes to evaluate the impact of cabazitaxel on quality of life (QoL). The final safety and QoL results from the Australian EAP for cabazitaxel are reported. Australian patients with mCRPC previously treated with a docetaxel-containing regimen received cabazitaxel (25 mg/m ) every 3 weeks plus prednisone/prednisolone (10 mg daily) until disease progression, death, unacceptable toxicity, physician's decision or patient's refusal of further treatment. QoL data was collected using the AQoL-8D questionnaire. 104 patients from 18 Australian sites (median age at baseline, 70) enrolled in the EAP and completed at least one AQoL-8D questionnaire. Patients received a median of 6 cycles of cabazitaxel. 67 patients (64.4%) experienced grade greater than or equal to3 treatment-emergent adverse events (TEAEs); the most frequent TEAEs were neutropenia, febrile neutropenia, diarrhoea, and vomiting. QoL scores remained stable with increasing treatment cycles."

According to the news editors, the research concluded: "The results suggest that the safety profile cabazitaxel is manageable in the Australian clinical practice setting and that QoL is maintained with little or no detrimental effect of cabazitaxel in patients continuing on treatment without disease progression."

For more information on this research see: Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program. Asia-pacific Journal of Clinical Oncology, 2017;():. Asia-pacific Journal of Clinical Oncology can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA. (Wiley-Blackwell -; Asia-pacific Journal of Clinical Oncology -

The news correspondents report that additional information may be obtained from P. Parente, Eastern Health Clinical School, Box Hill Hospital, Monash University, Melbourne, VIC, Australia. Additional authors for this research include S. Ng, F. Parnis, A. Guminski and H. Gurney.

The publisher's contact information for the Asia-pacific Journal of Clinical Oncology is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

Keywords for this news article include: Oncology, Melbourne, Prostate Cancer, Quality of Life, Disease Attributes, Disease Progression, Prostatic Neoplasms, Pathologic Processes, Australia and New Zealand.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Monash University
Sanofi-Aventis Australia Pty Ltd


Australia and New Zealand
North America
United States


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies